IL-35: A potential therapeutic target for controlling hepatitis B virus infection
IL-35: A potential therapeutic target for controlling hepatitis B virus infection
复制标题
IL-35：控制乙型肝炎病毒感染的潜在治疗靶点
DOI：
10.1111/1751-2980.12218
复制
发表时间：
2015-01-01
影响因子：
3.5
通讯作者：
Xie, Qing
中科院分区：
文献类型：
--
作者：
Xiang, Xiao Gang;Xie, Qing
白细胞介素（Interleukin， IL）-35是最近发现的IL-12家族细胞因子，是由调节性T （Treg）细胞和新报道的调节性B （Breg）细胞分泌的一种有效的免疫抑制细胞因子。IL-35在免疫介导的疾病中是一个重要的免疫抑制因子，其抑制的主要机制是其抑制T细胞增殖的能力和效应功能。非细胞病变性乙型肝炎病毒（HBV）感染相关肝病的致病过程是免疫介导的，包括肝损伤和病毒控制。研究发现，IL-35在慢性hbv感染患者的外周血CD4(+) T细胞中可检测到，而在健康个体中则检测不到。越来越多的证据表明，细胞因子介导的免疫反应在决定HBV感染期间的临床结果中起着关键作用。研究IL-35在慢性HBV感染免疫发病机制中的作用显得尤为重要。在本研究中，讨论了最近对这一问题的认识。
Interleukin (IL)-35, a recently identified cytokine of the IL-12 family, is a potent immunosuppressive cytokine secreted by regulatory T (Treg) cells and the newly reported regulatory B (Breg) cells. IL-35 functions as a crucial immunosuppressive factor in immune-mediated diseases, and the predominant mechanism of suppression is its ability to suppress T cell proliferation and effector functions. The pathogenic processes of the non-cytopathic hepatitis B virus (HBV) infection-related liver diseases are immune-mediated, including liver damage and viral control. It has been found that IL-35 is detectable in peripheral CD4(+) T cells in chronic HBV-infected patients, whereas it is undetectable in healthy individuals. There is growing evidence that cytokine-mediated immune responses play a pivotal role in determining the clinical outcome during HBV infection. It is particularly important to investigate the effects of IL-35 in the immunopathogenesis of chronic HBV infection. In this study, the recent understanding of this issue is discussed.